The University of Chicago Header Logo

Connection

Kenneth Gordon to Skin Diseases, Infectious

This is a "connection" page, showing publications Kenneth Gordon has written about Skin Diseases, Infectious.
Connection Strength

0.027
  1. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.